Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S V Stuart; Robert H Shaw; Xinxue Liu; Melanie Greenland; Parvinder K Aley; Nick J Andrews; J C Cameron; Sue Charlton; Elizabeth A Clutterbuck; Andrea M Collins; Tom Darton; Tanya Dinesh; Christopher J A Duncan; Anna England; Saul N Faust; Daniela M Ferreira; Adam Finn; Anna L Goodman; Christopher A Green; Bassam Hallis; Paul T Heath; Helen Hill; Bryn M Horsington; Teresa Lambe; Rajeka Lazarus; Vincenzo Libri; Patrick J Lillie; Yama F Mujadidi; Ruth Payne; Emma L Plested; Samuel Provstgaard-Morys; Maheshi N Ramasamy; Mary Ramsay; Robert C Read; Hannah Robinson; Gavin R Screaton; Nisha Singh; David P J Turner; Paul J Turner; Iason Vichos; Rachel White; Jonathan S Nguyen-Van-Tam; Matthew D Snape

Lancet (London, England) (2022) - Comments
pubmed: 34883053 doi: 10.1016/s0140-6736(21)02718-5 issn: 0140-6736 issn: 1474-547x

Arabella S V Stuart, Robert H Shaw, Xinxue Liu, Melanie Greenland, Parvinder K Aley, Nick J Andrews, J C Cameron, Sue Charlton, Elizabeth A Clutterbuck, Andrea M Collins, Tom Darton, Tanya Dinesh, Christopher J A Duncan, Anna England, Saul N Faust, Daniela M Ferreira, Adam Finn, Anna L Goodman, Christopher A Green, Bassam Hallis